Finance

Lists
Why is PBLS down 3.78%?
Dive Deeper
PBLS:NASDAQ
Parabilis Medicines Inc
$27.25
-3.78%
(-1.07) 1D
$27.25
0.00% (0.00)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PBLS...
Open
$28.13
High
$28.55
Low
$26.87
Mkt. cap
3.32B
Avg. vol.
1.12M
Volume
0.00
52-wk high
$42.48
52-wk low
$22.66
EPS
-$1.94
No. of employees
145
Open
$28.13
High
$28.55
Low
$26.87
Mkt. cap
3.32B
Avg. vol.
1.12M
Volume
0.00
52-wk high
$42.48
52-wk low
$22.66
EPS
-$1.94
No. of employees
145
News stories
From web sources and news partners
About Parabilis Medicines Inc
CEO-
Employees145
Founded2015
Headquarters-
SectorBiotechnology
Websiteparabilismed.com
Analyst ratings
Based on 5 analysts giving stock ratings to PBLS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PBLS in the last 3 months.
Highest
Current $27.25
$45.00 (+65.14%)
Average
$41.75 (+53.21%)
Lowest
$40.00 (+46.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
10/26/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$40.00
+46.8%
10/26/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$45.00
+65.1%
10/26/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$40.00
+46.8%
08/14/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$42.00
+54.1%
08/13/2026
Gaurav Maini
LifeSci Capital
Buy
Initiated
$42.00
+54.1%
07/18/2026
Andrew Berens
Leerink Partners
Buy
Initiated
$40.00
+46.8%
07/06/2026
Next call in 11 days
Fri, Nov 13, 4:00 PM
Fiscal period
Q3 2026
- / -$0.38
Revenue / Est. (USD)
- / 500.00K
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
148.00K
Cost of goods sold
-
30.13M
-
39.38M
Cost of revenue
-
30.13M
-
39.38M
Research and development expenses
33.90M
-
37.75M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.28M
5.34M
9.70M
11.66M
Operating expense
39.18M
5.34M
47.45M
11.66M
Total operating expenses
39.18M
35.46M
47.45M
51.03M
Operating income
-39.18M
-35.46M
-47.45M
-50.89M
Other non operating income
-
-
-
-5.56M
EBT including unusual items
-38.33M
-34.81M
-45.32M
-52.46M
EBT excluding unusual items
-38.33M
-34.81M
-45.32M
-52.46M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-38.33M
-34.81M
-45.32M
-52.46M
Net profit margin
-
-
-
-35,447.97%
Earnings per share
-
-
-
-2.12
Interest and investment income
1.26M
1.05M
2.43M
4.19M
Interest expense
-399.00K
-396.00K
-292.00K
-210.00K
Net interest expenses
858.00K
653.00K
2.14M
3.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-38.53M
-34.84M
-46.85M
-50.29M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps